The emergence of medications like copyright and Semaglutide signifies a major shift in how we manage blood sugar. These new therapies belong to a class known as GLP-1 action agonists, which mimic the effects of a natural hormone that regulates sugar levels and appetite. Originally, developed for diabetic conditions, their effectiveness in supportin